Answers are grounded in this paper and cite their sources.
Explores arginase role in chronic cutaneous leishmaniasis, suggesting dietary L-arginine as a treatment option.
Summary Background and research question: Infections with protozoan parasites of the genus Leishmania are a significant global health concern. Especially in highly endemic areas, efficient, safe and affordable treatment options are urgently needed. Studies in the Leishmania (L.) major C57BL/6 mouse model revealed that healing of cutaneous leishmaniasis (CL) and control of the parasites, which reside and proliferate within phagosomes of myeloid and non-myeloid cells, require type 1 T helper cell (Th1)- and interferon (IFN)γ-dependent induction of inducible nitric oxide synthase (NOS2). The enzyme NOS2 converts L-arginine into citrulline and microbicidal nitric oxide (NO). However, the activity of NOS2 is counteracted by arginase (ARG) 1 and 2 that are induced by Th2-derived cytokines and cleave L-arginine into urea and ornithine, a precursor of polyamines, which are necessary for parasite and immune cell proliferation. In previous studies of our group, non-healing, Th2-dominated progressive CL seen in L. major-infected BALB/c mice was linked to interleukin (IL)-4-dependent induction of ARG1 in the infected tissue. Unlike L. major infections, the immune response in L. mexicana-infected C57BL/6 and BALB/c mice is characterized by a mixed Th1/Th2 response, resulting in chronic CL in both strains of mice. Based on our findings in the L. major model, we postulated that ARG1 and/or ARG2 account for the chronicity of disease in L. mexicana-infected mice. Therefore, this thesis aimed to investigate the expression, regulation, function and mode of action of ARG1 and ARG2 during L. mexicana infection. Methods: C57BL/6N wild-type (WT) mice, germ-line knockout (Arg2-/-, Ifnγ-/-) mice and cell-specific conditional knockout mice (Arg1ΔTek, Arg1ΔTek Arg2-/-, Arg1ΔCx3cr1, Il10ΔCd4) were subjected to subcutaneous infection with 3×106 stationary-phase L. mexicana promastigotes. In order to inhibit partially the infection-induced IFNγ response, C57BL/6N mice infected with L. mexicana received biweekly intraperitoneal injections of 50 µg of blocking anti-mouse IFNγ or the respective isotype control antibody. For dietary L-arginine supplementation, L-arginine-HCl (40 g/L) was applied in acidified tap water (pH 3), freshly prepared every 3-4 days. mRNA and protein expression levels in target organs (skin lesions and draining lymph nodes [dLN]) was assessed by reverse transcriptase quantitative polymerase chain reaction and western blot techniques. Cytokines in tissue lysates or plasma of infected mice were quantified by sandwich enzyme-linked immunosorbent assay. Flow cytometry and immunofluorescence-based confocal laser scanning microscopy were used for determination of the composition and in situ localization of immune cells, respectively. Transcriptomics and metabolomics analyses were performed employing single-cell RNA sequencing (scRNAseq) and liquid chromatography-mass spectrometry (LC-MS), complemented by rigorous bioinformatics assessments. Results: C57BL/6 WT mice developed the expected non-healing skin lesions, while Arg2-/- mice showed a delayed-onset but still progressive disease. In contrast, mice lacking ARG1 expression in hematopoietic and endothelial cells (Arg1ΔTek) and mice deficient for both ARG1 and ARG2 (Arg1ΔTekArg2-/-) developed only mild pathology and resolved their skin lesions despite parasite persistence. A similar outcome was observed in mice deficient for ARG1 in monocytes and macrophages (Arg1ΔCx3cr1), demonstrating that myeloid ARG1 accounts for the chronicity of CL. The analysis of mice lacking IL-10 in CD4+ T cells (Il10ΔCd4) revealed that T cell-derived IL-10 is critical for the induction of ARG1. Metabolomic studies uncovered that elevated ARG1 expression led to a long-lasting L-arginine depletion and a concomitant increase of polyamines within infected WT skin lesions and dLNs. To unravel the mechanism of ARG1-dependent pathology, we studied L. mexicana-infected mice at day 40 after infection, when ARG1 was already upregulated in WT mice, but disease manifestation, parasite burden and metabolic profiles were still comparable in WT and ARG1-deficient mice. As much more NOS2 protein was present in the infected WT skin, levels of NO detected in WT and ARG1-deficient mice were remarkably similar at this time-point. However, using scRNAseq analysis of viable skin lesion cells, distinct myeloid subpopulations were enriched in WT mice, notably an ARG1+NOS2+ cluster of inflammatory macrophages. Bioinformatic analysis and sorting of these cells followed by Leishmania staining revealed that these macrophages form a parasite replication niche due to ARG1 and NOS2 substrate competition. Trajectory analysis suggested an altered differentiation of recruited monocytes in the presence of ARG1. The Cx3cr1-dependent ARG1 expression in the skin was associated with an increased IFNγ release by infiltrating CD4+ T cells. Together with ARG1, IFNγ stimulated the differentiation of newly recruited Ly6C+CD62L+Cx3cr1+ monocytes into inflammatory macrophages that co-expressed ARG1, NOS2, CXCL9 and CXCL10. These chemokines, in turn, attracted additional monocytes, which led to a self-perpetuating cycle of ARG1-mediated pathology. The accumulation of ARG1+NOS2+ macrophages in infected WT mice resulted in a profound and long-lasting depletion of L-arginine, particularly at the skin site, which did not occur in ARG1-deficient mice. Prophylactic oral application of L-arginine prevented the development of chronic CL. L-arginine treatment of mice with established skin lesions led to clinical cure, which was preserved even after cessation of the therapy. Conclusions: ARG1-dependent signals drive a pathogenic monocyte differentiation in the skin of L. mexicana-infected mice, which is characterized by a self-amplifying monocyte influx and the emergence of an ARG1+/NOS2+ host cell niche that supports parasite replication and leads to L-arginine depletion. Dietary replenishment of the L-arginine pool allows for resolution of disease. These findings suggest L-arginine as a novel treatment option for chronic CL.
No takes yet. Share an insight, caveat, or question.
Baplu Rai (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: